title: High mortality among older patients treated with pentavalent antimonials for visceral leishmaniasis in East Africa and rationale for switch to liposomal amphotericin B.
authors.forename: François
authors.initials: F
authors.lastname: Chappuis
authors.forename: Emilie
authors.initials: E
authors.lastname: Alirol
authors.forename: Dagemlidet T
authors.initials: DT
authors.lastname: Worku
authors.forename: Yolanda
authors.initials: Y
authors.lastname: Mueller
authors.forename: Koert
authors.initials: K
authors.lastname: Ritmeijer
mesh_terms: D000349:Africa; D000367:Age Factors; D000666:Amphotericin B / Q000627:therapeutic use*; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D006801:Humans; D007898:Leishmaniasis, Visceral / Q000188:drug therapy* / Q000401:mortality*; D008875:Middle Aged
chemical_list: D000981:Antiprotozoal Agents; C068538:liposomal amphotericin B; D000666:Amphotericin B